Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fi
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group’s trust account be...
Source: pharmiweb.com
